6Elsie S, Joseph L, Michale N, et al. The association of Epstein-Barr Virus with smooth-muscle tumors occurring after organ transplantation. N Engl J Med,1995,332:19 -25.
8Camardo J. The Rapamune era of immunosuppression 2003 : the journey from the laboratory to clinical transplatation. Transplant Proc, 2003,35 : 18 - 24.
4Vallejo GH, Romero C J, de Vicente JC, et al. Incidence and risk factors for cancer after liver transplantation. Crit Rev Oncol Hematol,2005, 56 : 87-99.
5Lee TC, Savoldo B, Rooney CM, et al. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant, 2005, 5:2222-2228.
6Tremblay F, Fernandes M, Habbab F, et al.Mal ignancy after renal transplantation:incidence role of type of immunosuppression. Ann Surg Oncol, 2002,9(8) :785-788.
7Bi rkeland SA,Storm H, Lamm L,et al. Cancer:risk aftier renal tranplantation in the Nordic coun-tries. Int J Cancer,1995,9(2):183-186.
8Penn I.The changing pattern of posttransplant malignancies.Transplant Proc, 1991,23(11):1101-1105.
9Song Mon, Lu Jiamei. Management of tongue cancer in the patient who is systemically immunosuppressed:a preliminary report. Oral Surg Oral Pathd Oral Radiol Endod,2000,90:689-693.
10Guba M,Breitenbuch PV, Steinbauer M,et al.Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis involvement of vascular endothelial growth factor. Nature Medicine,2002,8(4):128.
